**Authors\' reply**

Sir---Lowell Wood raises concerns about our analysis of SARS coronavirus (SARS-CoV) strains, questioning the small number of mutations described. Although Wood is correct in his theoretical calculations, which are based on generalised in-vitro experiments, three explanations can be invoked to address his concerns.

First, despite a high mutational frequency of the SARS-CoV, the ultimate clone that emerges is dependent on positive and negative in-vivo selection; only those clones that have a replicative benefit (even a small advantage) will emerge as the dominant isolate. Since our sequencing method is based on direct analysis of PCR products, the full mutational heterogeneity in a viral population from one individual cannot be estimated. For example, a mutation that is present in only one in 1000 viruses within one isolate will simply not be detected, nor is it likely to be biologically important.

Second, only a fraction of the viral particles present in body fluid is capable of infection, with that fraction highly dependent on the presence of antibodies, the viral load of the patient, the source of the body fluid, and the amount of time that the fluid is out of the host\'s body. Thus, Wood\'s assumption that every viral particle in a host could be infectious and equally capable of passage is incorrect and would result in a gross overestimate of in-vivo viral genetic diversity.

Third, the dynamic of the SARS epidemic is dependent on infection by a small number of so-called superspreaders. This pattern would, in effect, result in the clonal expansion of a limited number of viral isolates in this SARS-CoV epidemic. Taken together, clinical and in-vivo studies of limited isolates from early branch cases derived from only two or three index cases can be expected to show modest genetic diversity severely restricted by chance events, such as case contacts, and by biological selection.
